Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions.
Pancreatic ductaladeno carcinoma (PDAC) is a deadly cancer characterized by multiple molecular alterations, the presence of an intense stroma, poor perfusion, and resistance to therapy. In addition to standard imaging techniques, experimental imaging strategies, such as those utilizing molecular probes, nanoparticle-based agents, and tagged antibodies are actively being explored experimentally. It is hoped that advances in these technologies will allow for detecting PDAC at an early stage, and could serve to validate experimental therapies, rapidly identify non-responders, and assist in the design of novel therapeutic strategies tailored to the patient's molecular profile.
Indiana University School of Medicine, Indianapolis, IN, USA.
Gabriela
G
Kramer-Marek
Jesse
J
Gore
Murray
M
Korc
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000628:therapy; D000818:Animals; D021441:Carcinoma, Pancreatic Ductal / Q000175:diagnosis* / Q000628:therapy; D003952:Diagnostic Imaging / Q000379:methods*; D042241:Early Diagnosis; D006801:Humans; D051379:Mice; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000628:therapy; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
Molecular imaging; PDAC; Ultrasonography